The latest updates you cannot miss.
Edition 1 | 2025
Breaking News
Unveil the Future of Radiochemistry with IBA
IBA pushed the boundaries of radiochemistry and developed a new module. Cutting-edge science meets innovation for unmatched efficiency and versatility.
Be the first to discover it at iSRS (Australia) on Monday, May 12 at 3.30 PM at the IBA booth!
Framatome and IBA to partner to develop an Astatine-211 Cyclotron Network in Europe and the USA
IBA and Framatome signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (211At), an alpha-emitting radioisotope across Europe and the United States.
Discover our game-changing Helium Free Target!
Achieve more with less, with our Nirta® HeFree target, designed for excellence. This game-changing advancement is set to redefine your production standards.
The promises of our Nirta® HeFree target:
- Boosted productivity: Achieve up to 20% higher yield per run
- Enhanced safety: No activated parts remain on the cyclotron and maintenance reduced by half
- Cost efficiency: Reduce operational costs by using up to 50% less enriched water and no Helium at all, not even for pressurization
Supporting Cancer Care through European and National Research Projects Collaboration
IBA RadioPharma Solutions is proud to be actively part of several innovative projects focused on advancing precision Oncology and Theranostics: Accelerate.EU and Innovative Industrial Target Preparation (IITP). Others are in preparation and are to come.
Our educational webinars
New Webinar | 17.04.2025
Innovations and Future Outlook in Radiotheranostics
Explore the latest advancements in radiotheranostics in US and Europe, with the renowned Professor Ghesani, MD, FACNM, FSNMMI, FACR and Professor Deroose, MD.
Don't miss out on this opportunity to learn from one of the leading experts in the field.
Our latest webinar with Prof Dr Giesel and Prof Dr Levillain is available.
Targeted Alpha Therapy: Navigating the Path to Clinical Implementation and Future Outlook
- Latest advancements in radiopharmaceutical development
- Key clinical trials involving Actinium-225
- Early and upcoming trials with Astatine-211
Find out at which events to meet us next
